Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western population

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Ferrari, Daris ^a   Codecà, Carla ^a   Bertuzzi, Cecilia ^a   Broggio, Francesca ^a   Crepaldi, Francesca ^a   Luciani, Andrea ^a   Floriani, Irene ^b   Ansarin, Mohssen ^c   Chiesa, Fausto ^c   Alterio, Daniela ^c   Foa, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chemoradiotherapy; Epstein Barr virus; Induction chemotherapy; Nasopharyngeal carcinoma; Plasma EBV DNA copy numbers

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA EXTRACTION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GENE DOSAGE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BLOOD; CAUCASIAN; EPSTEIN BARR VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PROGNOSIS; RECURRENT DISEASE; VIROLOGY; VIRUS LOAD;

ADULT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; VIRAL LOAD;

EID: 84861566397     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-208     Document Type: Article

References (47)

1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents. VIIth edition. Lyon: International Agency for Research on Cancer; 1997:814-815. IARC Scientific Publications No.143.
2. Parkin D. Cancer Burden in the year 2000. The global Picture. Eur J Cancer 2001, 37:S4-S66.
3. Nielsen NH, Mikkelsen F, Hansen JP. Nasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo population. Acta Pathol Microbiol Scand 1977, 85:850-858.
4. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:421-429.
5. Huang TB, Min HQ, Min HQ, Wang HM, Zhang EP, Hong MH. Nasopharyngeal Carcinoma Research. Guangzhou: Guangdong Science and Technology Press; 1998:6-12.
6. Devi BCR, Pisani P, Tang TS, et al. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 2004, 13:482-486.
7. Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012. doi: 10.5732/cjc.011.10328. Epub ahead of print.
8. Micheli A, Francisci S, Krogh V, Rossi AG, Crosignani P. Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group. Tumori 1999, 85:309-369.
9. Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL, Khoo Tan HS, Lee KS, Lee KM, Tan T, Chua EJ. Prognostic factors in 677 patients in Singapore with non disseminated nasopharyngeal carcinoma. Cancer 1999, 86:1912-1920.
10. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997, 37:985-996.
11. Qin DX, Hu YH, Yan JH, Xu GZ, Cai WM, Wu XL, Cao DX, Gu XZ. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988, 61:1117-1124.
12. Ma J, Mai H, Hong M, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001, 19:1350-1357.
13. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985, 36(5):545-547. 15.
14. Ji MF, Yu YL, Cheng WM, Zong YS, Ng PS, Chua DT, Ng MH. Detection of stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J Cancer 2011, 30:120-123.
15. Chan JKC, Pilch BZ, KUO TT, Wenig BM, Lee AWM. World Health Organization: Pathology and Genetics Head and Neck Tumours. In Classification of Tumours. Tumours of the nasopharynx. Edited by Barnes L, Eveson JW, Reichart P, Sidransky D. Lyon:; 2005:81-106.
16. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001, 3(1):1-10.
17. Marks JE, Phillips JL, Menck HR. The National Cancer Database report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
18. Herrmann K, Niedobitek G. Epstein-Barr virus-associated carcinomas: facts and fiction. J Pathol 2003, 199:140-145.
19. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992, 66:2689-2697.
20. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
21. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006, 80:6458-6468.
22. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T, Kallin B. Expression of Epstein-Barr virusencoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988, 42:329-338.
23. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004, 26(7):598-602.
24. Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, Zheng BJ, Ji MF, Liang JS, Sham JST, Wang DK, Zong YS, Ng MH. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002, 97(4):489-492.
25. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000, 6:1046-1051.
26. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:5452-5455.
27. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ. Molecular Prognostication of Nasopharyngeal Carcinoma by Quantitative Analysis of Circulating Epstein-Barr Virus DNA. Cancer Res 2000, 60:6878-6881.
28. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59(6):1188-1191.
29. Liu Y, Fang Z, Liu L, Yang S, Zhang L. Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer: a meta-analysis. Genet Test Mol Biomarkers 2011, 15(7-8):495-502.
30. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma- specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005, 43:3066-3073.
31. Hong RL, Lin CY, Ting LL, Ko JY, Hsu MM. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA. Cancer 2004, 100(7):1429-1437.
32. Bortolin MT, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S, Tedeschi R, De Paoli P. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. Cancer Lett 2006, 233:247-254.
33. Greene FL, Page DL, Fleming ID, American Joint Committee on cancer, et al: AJCC cancer staging manual. 6th edition. Philadelphia: Lippincott-Raven; 2002.
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
35. Van Dongen JJM, Langerak AW, Bruggermann M, Evans P, Hummel M, Lavender FL, Delabesse E, Davi F, Schurring E, Garcia-Sanz R, Van Krieken JHJM, Droese J, Gonzalez D, Bastard C, White HE, Spaargar M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. Report of the BIOMED-2 Concerted Action BMH4-CT98-3936: Section 10: Use of Biomed-2 protocols with DNA extracted from paraffin-embedded tissue biopies and development of control gene primer set. Leukemia 2003, 17:2301-2304.
36. Wright CF, Reid AH, Tsai MM, Ventre KM, Murari PJ, Frizzera G, O'Leary TJ. Detection of epstein-barr virus sequences in hodgkin's disease by the polymerase chain reaction". Am J Pathol 1991, 139:393-398.
37. Chou J, Lin Y, Kim J, You L. Nasopharyngeal carcinoma-Review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30:946-963.
38. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350(24):2461-2470. 10.
39. Hou X, Zhao C, Guo Y, et al. Different clinical significance of pre- and posttreatment plasma Epstein- Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011, 23(2):128-133.
40. Leung S, Zee B, Ma BB, et al. Plasma epstein-barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006, 24:5414-5418.
41. Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 68 (5):1342-1348.
42. Chan ATC, Lo YMD, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Nat Cancer Inst 2002, 94(21):1614-1619.
43. Wang WY, Twu CW, Lin WY, Jiang RS, Liang KL, Chen KW, Wu CT, Shih YT, Lin JC. Plasma Epstein-Barr virus DNA screening followed by 18 F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 2011, 117:4452-4459.
44. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010, 16:1016-1024.
45. Li YH, Wang FH, Jiang WQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2008, 62:539-544.
46. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer 2005, 103:569-575.
47. An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011, 117 (16):3750-3757.